TriSalus Life Sciences IPO

TriSalus Life Sciences is a biopharma company that specializes in treatment research and development for tumors of the liver and pancreas. TriSalus involves a team of clinicians and scientists who develop systemic immunotherapies to fight tumors through its developed drug delivery methods.

Register for Details

For more details on financing and valuation for TriSalus Life Sciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is TriSalus Life Sciences's ticker symbol?

TriSalus Life Sciences does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

What is TriSalus Life Sciences's stock price?

The stock price for TriSalus Life Sciences will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

TriSalus Life Sciences Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
10/5/2022 Series B-2 $375.88MM $XXX.XX $XXX.XX
9/29/2021 Series B-1 and B-3 $356.56MM $XXX.XX $XXX.XX
3/18/2021 Series B $161.99MM $XXX.XX $XXX.XX
3/2/2017 Series A-6 $80.61MM $XXX.XX $XXX.XX
12/2/2015 Series A-4 and A-5 $55.51MM $XXX.XX $XXX.XX
11/7/2013 Series A-2 and A-3 $45.95MM $XXX.XX $XXX.XX
7/6/2011 Series A-1 $18.65MM $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about TriSalus Life Sciences

Forge green plus iconForge green minus icon

What is TriSalus Life Sciences funding to date?

TriSalus Life Sciences has raised $198.81MM with the following series:
$18.65MM for Series A-1, $45.95MM for Series A-2 and A-3, $55.51MM for Series A-4 and A-5, $80.61MM for Series A-6, $161.99MM for Series B, $356.56MM for Series B-1 and B-3, $375.88MM for Series B-2, $18.65MM for Series A-1, $45.95MM for Series A-2 and A-3, $55.51MM for Series A-4 and A-5, $80.61MM for Series A-6, $161.99MM for Series B, $356.56MM for Series B-1 and B-3, $375.88MM for Series B-2.
Forge green plus iconForge green minus icon

When was TriSalus Life Sciences founded?

TriSalus Life Sciences was founded in 2009.
Forge green plus iconForge green minus icon

Can you invest in TriSalus Life Sciences?

TriSalus Life Sciences is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell TriSalus Life Sciences share pre-IPO?

If you own TriSalus Life Sciences pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is TriSalus Life Sciences a publicly traded company?

TriSalus Life Sciences is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Other companies like TriSalus Life Sciences in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
 
 
Sector
Last Round Est. Valuation
$1.08B